For the quarter ending 2025-09-30, LIPO had -$926,058 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash stock option expense | - | 0 |
| Net loss | -1,254,078 | -2,634,009 |
| Depreciation and amortization | 722 | 1,443 |
| Operating right of use asset | 1,258 | -849 |
| Shares issued for services | - | 0 |
| Grants receivable | -41,981 | -42,731 |
| Prepaid expense | -389,921 | 265,761 |
| Accounts payable | -145,219 | 219,920 |
| Accrued expenses | 19,852 | -222,800 |
| Payroll liability | 19,505 | 62 |
| Net cash used in operating activities | -926,057 | -2,859,264 |
| Proceeds from issuance of common stock, preferred stock, and/or pre-funded warrants, net of issuance costs | 0 | 3,456,228 |
| Net cash provided by financing activities | 0 | 3,456,228 |
| Net cash used in investing activities | - | 0 |
| Net decrease in cash, cash equivalents | -926,058 | 596,965 |
| Cash and cash equivalents at beginning of period | 2,184,863 | - |
| Cash and cash equivalents at end of period | 1,855,770 | - |
LIPELLA PHARMACEUTICALS INC. (LIPO)
LIPELLA PHARMACEUTICALS INC. (LIPO)